Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

Concord, N.H. – Today, the Senate voted on three bills to protect and expand abortion rights in New Hampshire. Senators voted on party lines in opposition to CACR 24 and SB 575 and voted in favor of an amended version of SB 567. CACR 24 and SB 575 will not continue in the legislative process.

After the vote, Kayla Montgomery, Vice President for Public Affairs at Planned Parenthood of Northern New England and Planned Parenthood New Hampshire Action Fund, released the following statement:

“While we are deeply disappointed by the New Hampshire Senate’s opposition today to two critical reproductive rights bills, we are encouraged to see bipartisan support for establishing a state plan to respond to the upcoming Supreme Court decision on mifepristone, and we look forward to continuing to educate the House on the importance of access to mifepristone. 

Since Roe v. Wade was overturned in June 2022, the state of New Hampshire has failed to protect Granite Staters’ abortion rights, despite having multiple opportunities. The two pieces of legislation voted down today would have protected and expanded Granite Staters’ right to safe, legal abortion and ensure our state’s trusted providers are not penalized for providing appropriate and compassionate care, and it’s unfortunate that this important legislation will not be moving forward.

The majority of Granite Staters agree – everyone should have the right to make personal, private health care decisions in consultation with their medical providers, not politicians. It’s past time for our state laws to reflect the will of the people.”

Background on the legislation considered today:

CACR 24 would amend the New Hampshire Constitution to enshrine the right to reproductive freedom, recognizing that individuals have the right to make decisions about their own bodies and reproductive choices. 

  • New Hampshire has a long, bipartisan history of supporting privacy when it comes to personal medical decisions. CACR 24 also acknowledges that personal reproductive choices play a pivotal role in determining one's life course.

  • Where Granite Staters stand: Support: 785 | Oppose: 460

SB 575 provides protection for reproductive health care services, including for patients traveling to New Hampshire from states where abortion is restricted or banned. 

  • This bill ensures individuals have access to essential care in New Hampshire without fear of retribution from their own home state. 

  • Specifically, this bill prioritizes patient confidentiality by restricting the sharing of information related to reproductive health care services with out-of-state agencies, departments, or individuals without patient consent or a valid court-issued search warrant.

  • Where Granite Staters stand: Support: 697| Oppose: 210

SB 567 highlights and emphasizes the importance of access to medication abortion in New Hampshire, specifically mifepristone. 

  • A bipartisan amendment passed which directs the Department of Health and Human Services to compile a report on the availability of mifepristone and misoprostol. 

  • In December, the U.S. Supreme Court announced that it will consider a court challenge to the Federal Drug Administration's approval of mifepristone. Mifepristone is safe, effective, and has been used by more than five million people in the United States since the FDA approved it more than 20 years ago.

  • Mifepristone has helped ensure that patients are able to make their own private medical decisions and has expanded access to reproductive health care —something that is under dire threat in this country. In New Hampshire, medication abortion has helped people in rural areas with little access to care and people who can't travel or take time away from work, safely access abortion.

  • Oral arguments in this case will be on March 26.

  • Where Granite Staters stand: Support: 693 | Oppose: 214

Additional background about the mifepristone case at the U.S. Supreme Court:

A group of anti-abortion activists and organizations sued the U.S. Food and Drug Administration (FDA) over its approval of mifepristone, one of two medications most commonly used in medication abortion in the United States. In the case that originated in Texas, Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al, the plaintiffs asked the court to order the FDA to rescind its approval of mifepristone from more than 20 years ago, in order to remove it from the market. On April 21st, the Supreme Court of the United States granted the stay requested by the Department of Justice (DOJ) and Danco in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al. allowing mifepristone’s FDA approval to remain unchanged as the case proceeds through the Fifth Circuit Court of Appeals and the Supreme Court. This case will now be heard at the Supreme Court. Oral arguments are scheduled for March 26th.

Mifepristone is used exclusively early in pregnancy (before 11 weeks, or 77 days after a patient’s last missed period). In the 20 years since approved by the FDA, mifepristone has been used by more than five million people in the U.S. and is used in over half of all abortions in the United States. At Planned Parenthood of Northern New England (PPNNE), which has health centers in Maine, New Hampshire, and Vermont, about 70% of abortion patients choose medication abortion. 

Recent polling related to reproductive rights and abortion access: 

  • By a 20-point margin, likely voters think that medication abortion should be provided by mail and that the U.S. government should continue to allow telemedicine for abortion.

  • 54% of Republican 2024 primary voters in NH believe that abortion should be legal in all or most cases.

  • A survey from Breakthrough Campaigns conducted on behalf of Amplify NH shows that a supermajority of Granite Staters - 87% - support reproductive freedom and 64% of Granite Staters expect state elected officials to protect or expand abortion access in New Hampshire. Just 11% of Granite Staters want more abortion restrictions in the state.

  • In a 50-state survey, PRRI found most Americans oppose abortion ban policies; 69% of Granite Staters believe abortion should be legal in all or most cases.

  • August 2022 polling by the Saint Anselm College Survey Center shows that support for abortion rights in New Hampshire is at a historic high and nearly 6 in 10 voters disapproved of the overturning of Roe v. Wade on June 24, 2022.

  • Polling released in July 2021 from the UNH Survey Center shows that New Hampshire’s abortion ban is deeply unpopular, with only one-third of Granite Staters in support of it. Nearly half of independent Granite Staters oppose this ban, as do 27 percent of Republicans.

  • The truth is, most Granite Staters and most Americans support access to safe, legal abortion. If someone has decided to have an abortion, more than 8 in 10 respondents want the experience to be supportive and nonjudgmental, without added burdens or protesters, affordable and safe.

For more information on the legislation or to connect with a Planned Parenthood Northern New England spokesperson, contact [email protected] or (603) 715-4321.


Planned Parenthood New Hampshire Action Fund (PPNHAF) is an independent, nonpartisan, not-for-profit organization formed as the advocacy and political arm of Planned Parenthood of Northern New England in New Hampshire. The Action Fund engages in educational and electoral activity, including voter education, grassroots organizing, and legislative advocacy.

Planned Parenthood of Northern New England (PPNNE) is the largest provider of reproductive and sexual health care across the State of New Hampshire. We serve New Hampshire residents through 5 health centers in Derry, Exeter, Keene, Manchester and White River Junction, VT. Last fiscal year we saw more than 11,000 patients at these sites. PPNNE was named a 2021 Guardian of Excellence Award® winner by Press Ganey, the national leader in health care consumer and workforce engagement. Press Ganey recognizes PPNNE as a top-performing health care organization, achieving the 95th percentile or above for performance in patient experience. 

Planned Parenthood cares about your data privacy. We and our third-party vendors use cookies and other tools to collect, store, monitor, and analyze information about your interaction with our site to improve performance, analyze your use of our sites and assist in our marketing efforts. You may opt out of the use of these cookies and other tools at any time by visiting Cookie Settings. By clicking “Allow All Cookies” you consent to our collection and use of such data, and our Terms of Use. For more information, see our Privacy Notice.

Cookie Settings

Planned Parenthood cares about your data privacy. We and our third-party vendors, use cookies, pixels, and other tracking technologies to collect, store, monitor, and process certain information about you when you access and use our services, read our emails, or otherwise engage with us. The information collected might relate to you, your preferences, or your device. We use that information to make the site work, analyze performance and traffic on our website, to provide a more personalized web experience, and assist in our marketing efforts. We also share information with our social media, advertising, and analytics partners. You can change your default settings according to your preference. You cannot opt-out of our Necessary Cookies as they are deployed to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information, please see our Privacy Notice.



We use online advertising to promote our mission and help constituents find our services. Marketing pixels help us measure the success of our campaigns.



We use qualitative data, including session replay, to learn about your user experience and improve our products and services.



We use web analytics to help us understand user engagement with our website, trends, and overall reach of our products.